🚀 VC round data is live in beta, check it out!
OKYO Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for OKYO Pharma and similar public comparables like Aardvark Therapeutics, Pliant Therapeutics, Seres Therapeutics, PolyPid and more.
OKYO Pharma Overview
About OKYO Pharma
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
Founded
2007
HQ
Employees
4
Website
Sectors
Financials (LTM)
EV
$80M
OKYO Pharma Financials
OKYO Pharma reported last 12-month revenue of —.
In the same LTM period, OKYO Pharma generated had net loss of ($7M).
Revenue (LTM)
OKYO Pharma P&L
In the most recent fiscal year, OKYO Pharma reported revenue of — and EBITDA of ($7M).
OKYO Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($7M) | XXX | XXX | XXX |
| Net Profit | ($7M) | XXX | ($5M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
OKYO Pharma Stock Performance
OKYO Pharma has current market cap of $84M, and enterprise value of $80M.
Market Cap Evolution
OKYO Pharma's stock price is $1.61.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $80M | $84M | 1.3% | XXX | XXX | XXX | $-0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOKYO Pharma Valuation Multiples
OKYO Pharma trades at (11.3x) EV/EBITDA.
OKYO Pharma Financial Valuation Multiples
As of April 11, 2026, OKYO Pharma has market cap of $84M and EV of $80M.
Equity research analysts estimate OKYO Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
OKYO Pharma has a P/E ratio of (12.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $84M | XXX | $84M | XXX | XXX | XXX |
| EV (current) | $80M | XXX | $80M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (11.3x) | XXX | XXX | XXX |
| EV/EBIT | (7.8x) | XXX | (11.3x) | XXX | XXX | XXX |
| P/E | (12.7x) | XXX | (18.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (44.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified OKYO Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
OKYO Pharma Margins & Growth Rates
OKYO Pharma's revenue in the last fiscal year grew by —.
OKYO Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.8M for the same period.
OKYO Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (23%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.8M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
OKYO Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Aardvark Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Pliant Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Seres Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| PolyPid | XXX | XXX | XXX | XXX | XXX | XXX |
| Lytix Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OKYO Pharma M&A Activity
OKYO Pharma acquired XXX companies to date.
Last acquisition by OKYO Pharma was on XXXXXXXX, XXXXX. OKYO Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by OKYO Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOKYO Pharma Investment Activity
OKYO Pharma invested in XXX companies to date.
OKYO Pharma made its latest investment on XXXXXXXX, XXXXX. OKYO Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by OKYO Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout OKYO Pharma
| When was OKYO Pharma founded? | OKYO Pharma was founded in 2007. |
| Where is OKYO Pharma headquartered? | OKYO Pharma is headquartered in United Kingdom. |
| How many employees does OKYO Pharma have? | As of today, OKYO Pharma has over 4 employees. |
| Who is the CEO of OKYO Pharma? | OKYO Pharma's CEO is Gary S. Jacob. |
| Is OKYO Pharma publicly listed? | Yes, OKYO Pharma is a public company listed on Nasdaq. |
| What is the stock symbol of OKYO Pharma? | OKYO Pharma trades under OKYO ticker. |
| When did OKYO Pharma go public? | OKYO Pharma went public in 2022. |
| Who are competitors of OKYO Pharma? | OKYO Pharma main competitors are Aardvark Therapeutics, Pliant Therapeutics, Seres Therapeutics, PolyPid. |
| What is the current market cap of OKYO Pharma? | OKYO Pharma's current market cap is $84M. |
| Is OKYO Pharma profitable? | No, OKYO Pharma is not profitable. |
| What is the current net income of OKYO Pharma? | OKYO Pharma's last 12 months net income is ($7M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.